Gapping up
In reaction to earnings/guidance:
- AZUL +21.4%, CIEN +10%, CECO +5.1%, RIDE +1.8%
Other news:
- BBIO +57.5% (Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events)
- TCRR +33.1% (Adaptimmune Therapeutics (ADAP) and TCR² Therapeutics (TCRR) announce strategic combination)
- MLYS +5.9% (Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC)
- ATAI +5.1% (Announces Key Clinical Pipeline and Corporate Updates)
- RLYB +4.9% (announced that clinical proof-of-concept has been achieved in a Phase 1b study for RLYB212)
- IVVD +3.4% (announces the election of VYD222 to advance into the clinic as a novel monoclonal antibody therapeutic option for COVID-19)
- CYTK +3.3% (Presents Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd Annual Scientific Session)
- SSB +2.5% (enters into separation and transition agreement with Exec Chairman)
- SLM +2% (CFO Steven McGarry to retire in Feb 2024; co is conducting an extensive search to identify his successor)
- ETNB +2% (Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology)
- NGL +1.4% (signs agreements to sell marine assets for $111.65 mln)
- GATO +1.3% (Provides Bi-Weekly Status Report)
- AMRN +1% (reports New REDUCE-IT Data at ACC.23/WCC Showing Benefit of VASCEPA/VAZKEPA (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event)
Analyst comments:
- VIR +5.1% (upgraded to Overweight from Neutral at JP Morgan)
- MTH +1.2% (upgraded to Overweight from Neutral at JP Morgan)